| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e13cf25eb1bef6199475314477618b46 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 |
| filingDate |
2017-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_104ede39c6684c7c8c8d909b7698d8ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5ddb5ed037f093a30eadd6090fae829
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6a5d3a861fdda8cba12c66fbd6e12ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ab0a81b843e2b6a1a5ebe3333f473b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddfc6b984c5aee9eca2276edf187c02d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7147d7dcf49151419391de11e3da6373 |
| publicationDate |
2021-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3828178-A1 |
| titleOfInvention |
Pyridine salts and process |
| abstract |
The present invention relates to a pharmaceutically acceptable salts of a compound having RET kinase inhibiting action. In particular pharmaceutically acceptable salts of a compound represented by the following general formula (I) as defined herein:The invention also relates to processes for the preparation of compounds of general formula (I). |
| priorityDate |
2016-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |